Entero Therapeutics, Inc. (ENTO)

Entero Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	3.74	1.4	8.29	6.09	0.22
Cash & Cash Equivalents	3.74	1.4	8.29	6.09	0.22
Cash Growth	166.98%	-83.09%	36.17%	2708.51%	-81.30%
Receivables	0	0.09	0	0.55	2.64
Other Current Assets	1.21	1.92	1.13	1.23	0.55
Total Current Assets	4.96	3.41	9.42	7.87	3.41
Property, Plant & Equipment	0.21	0.3	0.41	0.09	0.16
Goodwill and Intangibles	1.68	1.68	1.91	4.93	5.29
Other Long-Term Assets	0.03	0.04	0.04	0.03	0.04
Total Long-Term Assets	1.93	2.03	2.37	5.05	5.49
Total Assets	6.88	5.44	11.79	12.92	8.9
Accounts Payable	1.62	1.48	3.17	1.69	2.29
Current Debt	0.68	0.67	0.72	0.55	1.52
Other Current Liabilities	0.83	0.33	8.41	13.31	0.48
Total Current Liabilities	3.13	2.48	12.3	15.55	4.29
Long-Term Debt	0.15	0.21	0.31	0	0
Other Long-Term Liabilities	0	0	7	0.02	0
Total Long-Term Liabilities	0.15	0.21	7.31	0.02	0
Total Liabilities	3.28	2.7	19.61	15.56	4.29
Total Debt	0.83	0.88	1.03	0.55	1.52
Debt Growth	-6.43%	-14.23%	86.52%	-63.69%	496.51%
Retained Earnings	-184.33	-168.53	-153.9	-95.37	-62.69
Comprehensive Income	0	0	-1.22	-1.11	-1.27
Shareholders' Equity	3.6	2.74	-7.82	-2.64	4.62
Net Cash / Debt	2.92	0.52	7.26	5.54	-1.3
Net Cash / Debt Growth	462.32%	-92.86%	31.14%	-	-
Net Cash Per Share	8.67	14.45	3417.57	8179.70	-2442.81
Working Capital	1.82	0.93	-2.88	-7.68	-0.88
Book Value Per Share	10.71	76.36	-3680.47	-3900.31	8647.56

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).